摘要
Pfizer和Ligand制药两公司正在联合开发拉索昔芬（lasofoxifene／Oporia）。后者属选择性雌激素受体调节剂，其首要适应证目标为预防和治疗绝经后妇女骨质疏松症。
同被引文献28
-
1赵国锋.用于制备顺式-1-{2-[4-(6-甲氧基-2-苯基-1,2,3,4-四氢化萘-1-基)苯氧基] 乙基}吡咯烷的中间体:中国,1502597[P].2004-06-09[J].CA,2000,134:4858-4858.
-
2赵国锋.用于制备顺式-1-{2-[4-(6-甲氧基-2-苯基-1,2,3,4-四氢化萘-1-基)苯氧基] 乙基}吡咯烷的中间体:中国,1502598[P].2006-08-23[J].CA,2000,134:4858-4858.
-
3Sano Y,Nakata K,Otoyama T,et al.An expeditious synthesis of lasofoxifene and nafoxidine via the novel threecomponent coupling reaction[J].Chem Lett,2007,36 (1):40-41.
-
4Shiina I,Sano Y,Nakata K,et al.Progress for production of lasofoxifene or analogue thereof:EP,1982981[P].2008-10-22.(CA 2007,147:2234881).
-
5Bindal RD,Durani S,Kapil RS,et al.Utility of 4-trimethylsiloxyphenyl magnesium bromide in Grignard reactions[J].Synth Commun,1982,5:405-407.
-
6Gellibert F,de Gouville AC,Woolven J,et al.Discovery of 4-{4-[3-(pyridin-2-yl) -1H-pyrazol-4-yl] pyridin-2-yl} -N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388):a potent,selective,and orally active transforming growth factor-β type I receptor inhibitor[J].J Med Chem,2006,49(7):2210-2221.
-
7Pravst I,Zupan M,Stavber S.Halogenation of ketones with N-halosuccinimides under solvent-free reaction conditions[J].Tetrahedron,2008,64 (22):5191-5199.
-
8Pravst I,Zupan M,Stavber S.Directed regioselectivity of bromination of ketones with NBS:solvent-free conditions versus water[J].Tetrahedron Lett,2006,47(27):4707-4710.
-
9Kalita B,Maitreyee SB,Barua NC.A convenient and selective method for preparation of enol acetates from ketones using montmorillonite KSF clay[J].Synth Commun,2002,32 (20):3181-3184.
-
10Maekawa H,Itoh K,Goda S,et al.Enantioselective electrochemical oxidation of enol acetates using a chiral supporting electrolyte[J].Chirality,2003,15 (1):95-100.
引证文献2
-
1李丹,王哲烽,王小妹,时惠麟.酒石酸拉索昔芬合成路线图解[J].中国医药工业杂志,2010,41(6):468-471. 被引量：2
-
2李高伟,王晓娟,赵文献,郭保国.2-苯基-1-(4-(1-吡咯乙氧基)苯基)乙酮的合成[J].化学研究与应用,2012,24(6):936-939. 被引量：2
二级引证文献4
-
1李高伟,王晓娟,赵文献,郭保国.2-苯基-1-(4-(1-吡咯乙氧基)苯基)乙酮的合成[J].化学研究与应用,2012,24(6):936-939. 被引量：2
-
2王晓娟,李高伟,刘澜涛,郭保国,刘瑛,赵文献.手性砌块3-(S)-氨基四氢呋喃合成研究[J].化学研究与应用,2014,26(4):552-555.
-
3陈韵翔,黄杨威,赵学清,李忠铭.萘福昔定的合成[J].中国医药工业杂志,2014,45(6):501-503.
-
4李修刚,张玲钰,杨航周,黄启鹏.β-芳氧基乙醇的合成方法改进研究[J].化学研究与应用,2017,29(10):1605-1608.
-
1拉索昔芬及其研究进展[J].中国医药技术与市场,2006,6(1):67-67.
-
2王蔚,艾敏.治疗骨质疏松症的新药Lasofoxifene[J].药学进展,2005,29(2). 被引量：1
-
3欧洲批准酒石酸拉索昔芬薄膜包衣片上市[J].世界临床药物,2009,30(6):382-382.
-
4辉瑞骨质疏松治疗药导致高死亡率引发安全性质疑[J].世界临床药物,2008,29(10):638-638.
-
5Cummings SR Ensrud K Delmas PD.拉索昔芬用于绝经后骨质疏松疗效分析[J].中国处方药,2010(3):39-39.
-
6陈韵翔,黄杨威,赵学清,李忠铭.萘福昔定的合成[J].中国医药工业杂志,2014,45(6):501-503.
-
7田玲.生物技术公司联合开发靶向抗体[J].国外医学情报,2003,24(4):38-38.
-
8王刚.雌激素受体调节剂Lasofoxifene Tartrate[J].药学进展,2002,26(3):188-190.
-
9沈雁.利塞膦酸钠防治绝经后妇女骨质疏松症的有效性和药理分析[J].海峡药学,2013,25(6):162-163. 被引量：3
-
10李丹,王哲烽,王小妹,时惠麟.酒石酸拉索昔芬合成路线图解[J].中国医药工业杂志,2010,41(6):468-471. 被引量：2
